View Financial HealthMINAPHARM Pharmaceuticals 배당 및 자사주 매입배당 기준 점검 0/6MINAPHARM Pharmaceuticals 은(는) 현재 수익률이 0.38% 인 배당금 지급 회사입니다.핵심 정보0.4%배당 수익률-19.0%자사주 매입 수익률총 주주 수익률-18.7%미래 배당 수익률n/a배당 성장률-8.0%다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향25%최근 배당 및 자사주 매입 업데이트Upcoming Dividend • Jun 29Upcoming dividend of ج.م2.80 per share at 1.3% yieldEligible shareholders must have bought the stock before 06 July 2023. Payment date: 10 July 2023. Payout ratio is a comfortable 6.2% but the company is not cash flow positive. Trailing yield: 1.3%. Lower than top quartile of Egyptian dividend payers (7.5%). Lower than average of industry peers (3.5%).Upcoming Dividend • Jun 20Upcoming dividend of ج.م2.92 per shareEligible shareholders must have bought the stock before 27 June 2022. Payment date: 29 June 2022. Payout ratio is a comfortable 7.8% but the company is not cash flow positive. Trailing yield: 1.9%. Lower than top quartile of Egyptian dividend payers (11%). Lower than average of industry peers (4.2%).Upcoming Dividend • May 19Upcoming dividend of ج.م2.70 per shareEligible shareholders must have bought the stock before 26 May 2021. Payment date: 30 May 2021. Trailing yield: 2.5%. Lower than top quartile of Egyptian dividend payers (8.2%). Lower than average of industry peers (4.2%).모든 업데이트 보기Recent updatesBoard Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.공시 • May 06MINAPHARM Pharmaceuticals, Annual General Meeting, Jun 02, 2026MINAPHARM Pharmaceuticals, Annual General Meeting, Jun 02, 2026, at 15:00 Egypt Standard Time. Location: cairo Egypt공시 • May 27MINAPHARM Pharmaceuticals, Annual General Meeting, Jun 18, 2025MINAPHARM Pharmaceuticals, Annual General Meeting, Jun 18, 2025, at 15:00 Egypt Standard Time. Location: tenth of ramadan EgyptNew Risk • May 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Egyptian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.7x net interest cover). Earnings have declined by 13% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Market cap is less than US$100m (ج.م2.34b market cap, or US$46.7m).Board Change • May 14No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.New Risk • Sep 11New major risk - Revenue and earnings growthEarnings have declined by 2.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.4x net interest cover). Earnings have declined by 2.6% per year over the past 5 years. Minor Risk Market cap is less than US$100m (ج.م1.83b market cap, or US$37.8m).Reported Earnings • Jun 04First quarter 2024 earnings released: EPS: ج.م0.37 (vs ج.م3.49 in 1Q 2023)First quarter 2024 results: EPS: ج.م0.37 (down from ج.م3.49 in 1Q 2023). Revenue: ج.م984.3m (up 1.2% from 1Q 2023). Net income: ج.م4.05m (down 90% from 1Q 2023). Profit margin: 0.4% (down from 4.0% in 1Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has increased by 31% per year, which means it is well ahead of earnings.New Risk • Mar 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (11% operating cash flow to total debt). High level of non-cash earnings (47% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (ج.م2.88b market cap, or US$60.2m).Valuation Update With 7 Day Price Move • Jan 25Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ج.م249, the stock trades at a trailing P/E ratio of 6x. Average trailing P/E is 8x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 219% over the past three years.Valuation Update With 7 Day Price Move • Nov 21Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ج.م238, the stock trades at a trailing P/E ratio of 5.7x. Average trailing P/E is 7x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 223% over the past three years.Reported Earnings • Aug 31Second quarter 2023 earnings released: EPS: ج.م7.92 (vs ج.م11.31 in 2Q 2022)Second quarter 2023 results: EPS: ج.م7.92 (down from ج.م11.31 in 2Q 2022). Revenue: ج.م1.07b (up 24% from 2Q 2022). Net income: ج.م87.7m (down 35% from 2Q 2022). Profit margin: 8.2% (down from 16% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has increased by 37% per year, which means it is tracking significantly ahead of earnings growth.Upcoming Dividend • Jun 29Upcoming dividend of ج.م2.80 per share at 1.3% yieldEligible shareholders must have bought the stock before 06 July 2023. Payment date: 10 July 2023. Payout ratio is a comfortable 6.2% but the company is not cash flow positive. Trailing yield: 1.3%. Lower than top quartile of Egyptian dividend payers (7.5%). Lower than average of industry peers (3.5%).Reported Earnings • Jun 01First quarter 2023 earnings released: EPS: ج.م3.86 (vs ج.م10.24 in 1Q 2022)First quarter 2023 results: EPS: ج.م3.86 (down from ج.م10.24 in 1Q 2022). Revenue: ج.م972.2m (up 22% from 1Q 2022). Net income: ج.م49.9m (down 60% from 1Q 2022). Profit margin: 5.1% (down from 16% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has increased by 46% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • May 22Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ج.م227, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 4x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 261% over the past three years.Reported Earnings • Dec 04Third quarter 2022 earnings released: EPS: ج.م17.41 (vs ج.م8.40 in 3Q 2021)Third quarter 2022 results: EPS: ج.م17.41 (up from ج.م8.40 in 3Q 2021). Revenue: ج.م984.6m (up 30% from 3Q 2021). Net income: ج.م184.0m (up 80% from 3Q 2021). Profit margin: 19% (up from 14% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Jul 20Investor sentiment improved over the past weekAfter last week's 16% share price gain to ج.م164, the stock trades at a trailing P/E ratio of 4.4x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 118% over the past three years.Upcoming Dividend • Jun 20Upcoming dividend of ج.م2.92 per shareEligible shareholders must have bought the stock before 27 June 2022. Payment date: 29 June 2022. Payout ratio is a comfortable 7.8% but the company is not cash flow positive. Trailing yield: 1.9%. Lower than top quartile of Egyptian dividend payers (11%). Lower than average of industry peers (4.2%).Valuation Update With 7 Day Price Move • May 31Investor sentiment improved over the past weekAfter last week's 15% share price gain to ج.م150, the stock trades at a trailing P/E ratio of 4.1x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 95% over the past three years.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Jan 10Investor sentiment improved over the past weekAfter last week's 18% share price gain to ج.م128, the stock trades at a trailing P/E ratio of 3.5x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 75% over the past three years.Upcoming Dividend • May 19Upcoming dividend of ج.م2.70 per shareEligible shareholders must have bought the stock before 26 May 2021. Payment date: 30 May 2021. Trailing yield: 2.5%. Lower than top quartile of Egyptian dividend payers (8.2%). Lower than average of industry peers (4.2%).Valuation Update With 7 Day Price Move • Apr 28Investor sentiment improved over the past weekAfter last week's 16% share price gain to ج.م99.28, the stock trades at a trailing P/E ratio of 4.1x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 18% over the past three years.Valuation Update With 7 Day Price Move • Apr 07Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ج.م84.88, the stock trades at a trailing P/E ratio of 3.5x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 1.0% over the past three years.Reported Earnings • Apr 04Full year 2020 earnings releasedThe company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: ج.م2.36b (up 15% from FY 2019). Net income: ج.م300.8m (up 113% from FY 2019). Profit margin: 13% (up from 6.9% in FY 2019). The increase in margin was driven by higher revenue.Valuation Update With 7 Day Price Move • Feb 08Investor sentiment improved over the past weekAfter last week's 34% share price gain to ج.م111, the stock is trading at a trailing P/E ratio of 5x, up from the previous P/E ratio of 3.7x. This compares to an average P/E of 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders over the past three years are 68%.Is New 90 Day High Low • Feb 03New 90-day high: ج.م86.57The company is up 15% from its price of ج.م75.13 on 05 November 2020. The Egyptian market is also up 15% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Pharmaceuticals industry, which is up 4.0% over the same period.Is New 90 Day High Low • Jan 12New 90-day high: ج.م85.89The company is up 15% from its price of ج.م75.00 on 14 October 2020. The Egyptian market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is flat over the same period.Reported Earnings • Dec 04Third quarter 2020 earnings released: EPS ج.م6.32The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: ج.م590.8m (up 17% from 3Q 2019). Net income: ج.م77.6m (up 247% from 3Q 2019). Profit margin: 13% (up from 4.4% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.Is New 90 Day High Low • Nov 30New 90-day high: ج.م80.50The company is up 4.0% from its price of ج.م77.15 on 01 September 2020. The Egyptian market is up 2.0% over the last 90 days, indicating the company outperformed over that time. However, its price trend is similar to the Pharmaceuticals industry, which is also up 4.0% over the same period.공시 • Jul 31Shaheer Wafik Saad El Bardisy acquired an additional 10% stake in MINAPHARM Pharmaceuticals (CASE:MIPH) for approximately EGP 100 million.Shaheer Wafik Saad El Bardisy acquired an additional 10% stake in MINAPHARM Pharmaceuticals (CASE:MIPH) for approximately EGP 100 million on July 26, 2020. Shaheer Wafik Saad El Bardisy bought 1.2 million shares and increased his stake to 10.89%. Shaheer Wafik Saad El Bardisy completed the acquisition of an additional 10% stake in MINAPHARM Pharmaceuticals (CASE:MIPH) on July 26, 2020.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: MIPH EG 시장에서 주목할만한 배당금을 지급하지 않으므로 지급이 안정적인지 확인할 필요가 없습니다.배당금 증가: MIPH EG 시장에서 주목할만한 배당금을 지급하지 않으므로 지급액이 증가하는지 확인할 필요가 없습니다.배당 수익률 vs 시장MINAPHARM Pharmaceuticals 배당 수익률 vs 시장MIPH의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (MIPH)0.4%시장 하위 25% (EG)1.3%시장 상위 25% (EG)6.2%업계 평균 (Pharmaceuticals)2.2%분석가 예측 (MIPH) (최대 3년)n/a주목할만한 배당금: MIPH 의 배당금( 0.38% )은 EG 시장에서 배당금 지급자의 하위 25%( 1.34% )와 비교해 주목할 만하지 않습니다.고배당: MIPH 의 배당금( 0.38% )은 EG 시장에서 배당금 지급자의 상위 25%( 6.19% )와 비교해 낮습니다.주주 대상 이익 배당수익 보장: MIPH EG 시장에서 주목할만한 배당금을 지급하지 않습니다.주주 현금 배당현금 흐름 범위: MIPH 배당금을 지급하고 있지만 회사에는 잉여현금흐름이 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YEG 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/23 04:29종가2026/05/21 00:00수익2025/09/30연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스MINAPHARM Pharmaceuticals는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Upcoming Dividend • Jun 29Upcoming dividend of ج.م2.80 per share at 1.3% yieldEligible shareholders must have bought the stock before 06 July 2023. Payment date: 10 July 2023. Payout ratio is a comfortable 6.2% but the company is not cash flow positive. Trailing yield: 1.3%. Lower than top quartile of Egyptian dividend payers (7.5%). Lower than average of industry peers (3.5%).
Upcoming Dividend • Jun 20Upcoming dividend of ج.م2.92 per shareEligible shareholders must have bought the stock before 27 June 2022. Payment date: 29 June 2022. Payout ratio is a comfortable 7.8% but the company is not cash flow positive. Trailing yield: 1.9%. Lower than top quartile of Egyptian dividend payers (11%). Lower than average of industry peers (4.2%).
Upcoming Dividend • May 19Upcoming dividend of ج.م2.70 per shareEligible shareholders must have bought the stock before 26 May 2021. Payment date: 30 May 2021. Trailing yield: 2.5%. Lower than top quartile of Egyptian dividend payers (8.2%). Lower than average of industry peers (4.2%).
Board Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
공시 • May 06MINAPHARM Pharmaceuticals, Annual General Meeting, Jun 02, 2026MINAPHARM Pharmaceuticals, Annual General Meeting, Jun 02, 2026, at 15:00 Egypt Standard Time. Location: cairo Egypt
공시 • May 27MINAPHARM Pharmaceuticals, Annual General Meeting, Jun 18, 2025MINAPHARM Pharmaceuticals, Annual General Meeting, Jun 18, 2025, at 15:00 Egypt Standard Time. Location: tenth of ramadan Egypt
New Risk • May 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Egyptian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.7x net interest cover). Earnings have declined by 13% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Market cap is less than US$100m (ج.م2.34b market cap, or US$46.7m).
Board Change • May 14No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
New Risk • Sep 11New major risk - Revenue and earnings growthEarnings have declined by 2.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.4x net interest cover). Earnings have declined by 2.6% per year over the past 5 years. Minor Risk Market cap is less than US$100m (ج.م1.83b market cap, or US$37.8m).
Reported Earnings • Jun 04First quarter 2024 earnings released: EPS: ج.م0.37 (vs ج.م3.49 in 1Q 2023)First quarter 2024 results: EPS: ج.م0.37 (down from ج.م3.49 in 1Q 2023). Revenue: ج.م984.3m (up 1.2% from 1Q 2023). Net income: ج.م4.05m (down 90% from 1Q 2023). Profit margin: 0.4% (down from 4.0% in 1Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has increased by 31% per year, which means it is well ahead of earnings.
New Risk • Mar 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (11% operating cash flow to total debt). High level of non-cash earnings (47% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (ج.م2.88b market cap, or US$60.2m).
Valuation Update With 7 Day Price Move • Jan 25Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ج.م249, the stock trades at a trailing P/E ratio of 6x. Average trailing P/E is 8x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 219% over the past three years.
Valuation Update With 7 Day Price Move • Nov 21Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ج.م238, the stock trades at a trailing P/E ratio of 5.7x. Average trailing P/E is 7x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 223% over the past three years.
Reported Earnings • Aug 31Second quarter 2023 earnings released: EPS: ج.م7.92 (vs ج.م11.31 in 2Q 2022)Second quarter 2023 results: EPS: ج.م7.92 (down from ج.م11.31 in 2Q 2022). Revenue: ج.م1.07b (up 24% from 2Q 2022). Net income: ج.م87.7m (down 35% from 2Q 2022). Profit margin: 8.2% (down from 16% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has increased by 37% per year, which means it is tracking significantly ahead of earnings growth.
Upcoming Dividend • Jun 29Upcoming dividend of ج.م2.80 per share at 1.3% yieldEligible shareholders must have bought the stock before 06 July 2023. Payment date: 10 July 2023. Payout ratio is a comfortable 6.2% but the company is not cash flow positive. Trailing yield: 1.3%. Lower than top quartile of Egyptian dividend payers (7.5%). Lower than average of industry peers (3.5%).
Reported Earnings • Jun 01First quarter 2023 earnings released: EPS: ج.م3.86 (vs ج.م10.24 in 1Q 2022)First quarter 2023 results: EPS: ج.م3.86 (down from ج.م10.24 in 1Q 2022). Revenue: ج.م972.2m (up 22% from 1Q 2022). Net income: ج.م49.9m (down 60% from 1Q 2022). Profit margin: 5.1% (down from 16% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has increased by 46% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • May 22Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ج.م227, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 4x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 261% over the past three years.
Reported Earnings • Dec 04Third quarter 2022 earnings released: EPS: ج.م17.41 (vs ج.م8.40 in 3Q 2021)Third quarter 2022 results: EPS: ج.م17.41 (up from ج.م8.40 in 3Q 2021). Revenue: ج.م984.6m (up 30% from 3Q 2021). Net income: ج.م184.0m (up 80% from 3Q 2021). Profit margin: 19% (up from 14% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Jul 20Investor sentiment improved over the past weekAfter last week's 16% share price gain to ج.م164, the stock trades at a trailing P/E ratio of 4.4x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 118% over the past three years.
Upcoming Dividend • Jun 20Upcoming dividend of ج.م2.92 per shareEligible shareholders must have bought the stock before 27 June 2022. Payment date: 29 June 2022. Payout ratio is a comfortable 7.8% but the company is not cash flow positive. Trailing yield: 1.9%. Lower than top quartile of Egyptian dividend payers (11%). Lower than average of industry peers (4.2%).
Valuation Update With 7 Day Price Move • May 31Investor sentiment improved over the past weekAfter last week's 15% share price gain to ج.م150, the stock trades at a trailing P/E ratio of 4.1x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 95% over the past three years.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Jan 10Investor sentiment improved over the past weekAfter last week's 18% share price gain to ج.م128, the stock trades at a trailing P/E ratio of 3.5x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 75% over the past three years.
Upcoming Dividend • May 19Upcoming dividend of ج.م2.70 per shareEligible shareholders must have bought the stock before 26 May 2021. Payment date: 30 May 2021. Trailing yield: 2.5%. Lower than top quartile of Egyptian dividend payers (8.2%). Lower than average of industry peers (4.2%).
Valuation Update With 7 Day Price Move • Apr 28Investor sentiment improved over the past weekAfter last week's 16% share price gain to ج.م99.28, the stock trades at a trailing P/E ratio of 4.1x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 18% over the past three years.
Valuation Update With 7 Day Price Move • Apr 07Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ج.م84.88, the stock trades at a trailing P/E ratio of 3.5x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 1.0% over the past three years.
Reported Earnings • Apr 04Full year 2020 earnings releasedThe company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: ج.م2.36b (up 15% from FY 2019). Net income: ج.م300.8m (up 113% from FY 2019). Profit margin: 13% (up from 6.9% in FY 2019). The increase in margin was driven by higher revenue.
Valuation Update With 7 Day Price Move • Feb 08Investor sentiment improved over the past weekAfter last week's 34% share price gain to ج.م111, the stock is trading at a trailing P/E ratio of 5x, up from the previous P/E ratio of 3.7x. This compares to an average P/E of 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders over the past three years are 68%.
Is New 90 Day High Low • Feb 03New 90-day high: ج.م86.57The company is up 15% from its price of ج.م75.13 on 05 November 2020. The Egyptian market is also up 15% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Pharmaceuticals industry, which is up 4.0% over the same period.
Is New 90 Day High Low • Jan 12New 90-day high: ج.م85.89The company is up 15% from its price of ج.م75.00 on 14 October 2020. The Egyptian market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is flat over the same period.
Reported Earnings • Dec 04Third quarter 2020 earnings released: EPS ج.م6.32The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: ج.م590.8m (up 17% from 3Q 2019). Net income: ج.م77.6m (up 247% from 3Q 2019). Profit margin: 13% (up from 4.4% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
Is New 90 Day High Low • Nov 30New 90-day high: ج.م80.50The company is up 4.0% from its price of ج.م77.15 on 01 September 2020. The Egyptian market is up 2.0% over the last 90 days, indicating the company outperformed over that time. However, its price trend is similar to the Pharmaceuticals industry, which is also up 4.0% over the same period.
공시 • Jul 31Shaheer Wafik Saad El Bardisy acquired an additional 10% stake in MINAPHARM Pharmaceuticals (CASE:MIPH) for approximately EGP 100 million.Shaheer Wafik Saad El Bardisy acquired an additional 10% stake in MINAPHARM Pharmaceuticals (CASE:MIPH) for approximately EGP 100 million on July 26, 2020. Shaheer Wafik Saad El Bardisy bought 1.2 million shares and increased his stake to 10.89%. Shaheer Wafik Saad El Bardisy completed the acquisition of an additional 10% stake in MINAPHARM Pharmaceuticals (CASE:MIPH) on July 26, 2020.